Blog
RSS FeedPosted by Michael Wonder on 27 Jan 2021
NICE recommends Revlimid for newly diagnosed multiple myeloma patients
27 January 2021 - Bristol Myers Squibb’s Revlimid (lenalidomide) has received a recommendation from the UK’s NICE for newly diagnosed ...
Posted by Michael Wonder on 26 Jan 2021
NICE publishes second appraisal consultation document for Zytiga
26 January 2021 - NICE has had another look at abiraterone acetate for the treatment of patients with newly diagnosed ...
Posted by Michael Wonder on 22 Jan 2021
NICE recommends Jyseleca (filgotinib) on NHS in landmark decision for rheumatoid arthritis
21 January 2021 - NICE guidance, for the first time in the UK, supports access to an advanced therapy for people ...
Posted by Michael Wonder on 21 Jan 2021
NICE publishes final guidance backing Jyseleca for rheumatoid arthritis
21 January 2021 - NICE has published its final appraisal determination recommending the use of Gilead Sciences and Galapagos’ Jyseleca ...
Posted by Michael Wonder on 20 Jan 2021
Patient involvement in relative effectiveness assessments in the European Network for Health Technology Assessment
20 January 2021 - Patient involvement in the process of producing health technology assessments has become increasingly important. In the ...
Posted by Michael Wonder on 20 Jan 2021
Amryt’s Myalepta scores NICE backing for rare lipid disorder
20 January 2021 - NICE has recommended Amryt Pharma’s Myalepta (metreleptin) for use within the NHS. ...
Posted by Michael Wonder on 16 Jan 2021
Strengthening patient outcome evidence in health technology assessment: a coproduction approach
13 January 2021 - NICE worked with patients and staff from six patient organisations to review existing health technology assessment ...
Posted by Michael Wonder on 16 Jan 2021
NICE’s approach to measuring value
5 January 2021 - Appleby asks whether COVID-19 vaccines would be considered cost effective using the NICE approach to measuring ...
Posted by Michael Wonder on 15 Jan 2021
NICE backs GSK’s Zejula in advanced ovarian cancer
15 January 2021 - The UK’s NICE has recommended the use of GlaxoSmithKline’s Zejula (niraparib) on the NHS for women ...
Posted by Michael Wonder on 08 Jan 2021
NICE no for BMS’ Opdivo for head and neck cancer
8 January 2021 - The UK’s NICE has turned down Bristol Myers Squibb’s immunotherapy Opdivo (nivolumab) for recurrent or metastatic ...
Posted by Michael Wonder on 04 Jan 2021
NICE collaboration on streamlined licensing and patient access process for new medicines opened on January 1st
4 January 2020 - Companies can now submit medicines for the new Innovative Licensing and Access Pathway following close collaboration between ...
Posted by Michael Wonder on 22 Dec 2020
Shared decision making is an integral part of healthcare, says NICE
22 December 2020 - Shared decision making between patients and clinicians should be embedded throughout healthcare services, says NICE, in draft ...
Posted by Michael Wonder on 22 Dec 2020
Shionogi’s novel antibiotic, Fetcroja (cefiderocol), has been selected by UK’S NICE/NHSE&I as part of an antimicrobial subscription style reimbursement model
21 December 2020 - NICE and the National Health Service England and Improvement have recognised the potential of Shionogi’s innovative ...
Posted by Michael Wonder on 16 Dec 2020
NICE recommends Novartis’ wet AMD drug Beovu
16 December 2020 - The UK’s NICE has recommended Novartis’ anti-VEGF treatment Beovu (brolucizumab) for routine NHS use in wet ...
Posted by Michael Wonder on 14 Dec 2020
NICE u-turn on Novartis' migraine drug Aimovig
14 December 2020 - In a rare move, NICE has reconsidered its position on Novartis migraine prevention treatment Aimovig (erenumab), ...